【关注度高】靶向药培美替尼改变了肝内胆管癌的治疗现状

The U.S. Food and Drug Administration (FDA) approved Incyte's latest targeted drug Pemazyre through the accelerated approval process on April 17, 2020, for the treatment of adults with advanced FCFR2 gene fusion cholangiocarcinoma that has been previously treated but failed to respond.

According to data from a study, the intrahepatic cholangiocarcinoma targeting drug pemigatinib can achieve an objective response rate of 35.5% and a disease control rate of 82% in the treatment of patients with cholangiocarcinoma. The median duration of response is 9.1 months, with up to 63% of patients having a response duration of greater than or equal to 6 months, and 18% of patients having a response duration of greater than or equal to 12 months. It is not difficult to see from these data that the targeted drug pemigatinib has a very significant effect on the disease control and prognosis improvement of intrahepatic cholangiocarcinoma. The targeted drug pemetinib has changed the current treatment status of intrahepatic cholangiocarcinoma.

Pemetinib has not been approved for sale in China, and it has not yet been included in the national medical insurance to provide everyone with preferential policies. This means that patients will not be able to buy pemetinib at all in the country. Faced with this situation, more patients choose to go to distant overseas countries to purchase medicines under huge financial pressure. However, this method costs a lot of manpower, material resources and financial resources, which is miserable. However, according to Medical Companion Travel, the pemetinib version is very cost-effective and has been well received by many patients. The specification is 13.5mgx14 tablets and the price is about 341,175$. However, because the price of the drug rises and falls with the fluctuation of the exchange rate in the market, the specific price of the drug is not stable. For more information about pemigatinib, please contact Medical Travel for details.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.